Multiple myeloma. A clinical review.
This group of proliferative diseases of the plasma cell line, in which manifestations of abnormal immunoglobulin production are associated with variable degrees of depressed antibody synthesis, pose fascinating problems crossing many clinical and research disciplines. The present state of diagnosis and clinical management is assessed.
D000477:Alkylating Agents / Q000627:therapeutic use; D000686:Amyloidosis / Q000150:complications; D000888:Antibodies, Anti-Idiotypic / Q000302:isolation & purification; D001536:Bence Jones Protein / Q000652:urine; D001772:Blood Cell Count; D001798:Blood Proteins / Q000032:analysis; D001853:Bone Marrow / Q000473:pathology; D001854:Bone Marrow Cells; D003520:Cyclophosphamide / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006362:Heavy Chain Disease / Q000150:complications; D006801:Humans; D007122:Immunoelectrophoresis; D007136:Immunoglobulins / Q000032:analysis; D007674:Kidney Diseases / Q000150:complications; D008558:Melphalan / Q000008:administration & dosage / Q000627:therapeutic use; D009101:Multiple Myeloma / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use; D011507:Proteinuria / Q000175:diagnosis
D000477:Alkylating Agents; D000888:Antibodies, Anti-Idiotypic; D001798:Blood Proteins; D007136:Immunoglobulins; D003520:Cyclophosphamide; D001536:Bence Jones Protein; D008558:Melphalan; D011241:Prednisone